Introducing Elument: Trailblazing the Future of Mental Health and Wellness

NASHVILLE, TN / ACCESSWIRE / January 16, 2024 / Elument,a trailblazer in mental health & wellness services, is proud to enter the market with a modern approach of integrating psychotherapy in conjunction with psychedelic medicine. Elument unlocks new pathways of transformation and embodies a commitment to the essential elements of well-being, aiming to provide a safe, evidence-based, and inclusive experience for all.

Elument represents a profound shift from conventional medicine towards integrative mental health and wellness, where medicine is utilized to accelerate the benefits of therapy. Elument’s practice offers groundbreaking mental health and wellness services, specializing in psychedelic-assisted therapy and focusing on an holistic approach to enhance healing and personal growth.

President Shannon Eubanks, PharmD, expressed her enthusiasm for this transformative brand, stating, ” In light of the growing mental health crisis, it is imperative that those in distress or struggling with treatment-resistant challenges are offered a lifeline. Our commitment is focused on supporting individuals on their journey as they gain insight into different aspects of themselves.”

There has never been a greater need for innovation in mental health care, with the World Health Organization (WHO) declaring mental health disorders as the leading cause of disability worldwide-impacting nearly one billion people. Elument stands at the forefront of mental health care, on a mission to pioneer solutions, offering hope and healing to Tennesseans.

Elument has established roots in the Nashville area, but this is just the beginning of its journey. “Access to the highest quality care is of the utmost importance to us, and we plan to take Elument to new horizons,” shared Eubanks. “The vision extends beyond Nashville, as Elument will strive to make transformative healing accessible to a wider community, ultimately redefining the future of mental health.”

About Elument:

Elument (“eh-luh-muhnt”) is a modern mental health and wellness company dedicated to providing safe, transformative services for its clients and community partners. Our team of highly trained clinicians are committed to evidence-based treatments that foster harmony of the mind, body, and spirit. Elument integrates mental health and wellness services, with a specialization in psychedelic-assisted therapy, thus addressing the needs of the whole person. By pairing mental health expertise with innovative therapies, Elument helps individuals rediscover their innate ability to heal.

We invite you to step into your element and embark on a journey to unlock your boundless potential. Visit our website at www.elument.com or follow Elument on LinkedIn to learn more about this innovative approach to mental health.

Follow us on:
LinkedIn
Facebook

For Further Information:
www.elument.com
Shannon Eubanks
info@elument.com

SOURCE: Elument

View the original press release on accesswire.com

Staff

Recent Posts

Avant Brands Announces $3.9 Million Private Placement of Unsecured Convertible Debenture Units

KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or…

2 hours ago

The International Myeloma Foundation Mourns the Passing of IMF Board Member and Support Group Leader Jack Aiello

STUDIO CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF)…

2 hours ago

Senti Bio Announces Reverse Stock Split

Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif.,…

2 hours ago

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI…

2 hours ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved…

2 hours ago